Castle Biosciences (NASDAQ: CSTL) net income
Castle Biosciences reported a net loss of $24.2m for fiscal 2025; in fiscal 2024 it reported a net profit of $18.2m. Earnings per share were −$0.83.
Castle Biosciences's best year of the last 8 was fiscal 2024. It reported a loss in 6 of those 8 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$24.2m | −232.4% | −7.0% | −$0.83 |
| 2024 | $18.2m | — | 5.5% | $0.66 |
| 2023 | −$57.5m | — | −26.1% | −$2.14 |
| 2022 | −$67.1m | — | −49.0% | −$2.58 |
| 2021 | −$31.3m | — | −33.3% | −$1.24 |
| 2020 | −$10.3m | −294.9% | −16.4% | −$0.54 |
| 2019 | $5.3m | — | 10.2% | $0.35 |
| 2018 | −$6.4m | — | −27.9% | −$5.33 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Castle Biosciences net income compared with its sector
By net income for its latest fiscal year, Castle Biosciences ranks 216th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Castle Biosciences, −7.0%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 214th | Inogen | −$22.7m | −6.5% |
| 215th | Mirum Pharmaceuticals | −$23.4m | −4.5% |
| 216th | Castle Biosciences | −$24.2m | −7.0% |
| 217th | ClearPoint Neuro | −$25.5m | −69.1% |
| 218th | Travere Therapeutics | −$25.5m | −5.2% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Castle Biosciences
- How much did Castle Biosciences earn in fiscal 2025?
- Castle Biosciences reported a net loss of $24.2m for fiscal 2025. In fiscal 2024 it reported a net profit of $18.2m.
- What are the earnings per share of Castle Biosciences?
- They were −$0.83 in fiscal 2025, compared with $0.66 in fiscal 2024.
- What was the most profitable year for Castle Biosciences?
- Of its last 8 fiscal years, fiscal 2024, with $18.2m.
- Where does Castle Biosciences rank in its sector by net income?
- It ranks 216th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Castle Biosciences come from?
- From the annual report (Form 10-K) that Castle Biosciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Castle Biosciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018. More on Castle Biosciences: the Castle Biosciences page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.